PureTech Health (PureTech Health) EBIT : $-22.62 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health EBIT?

PureTech Health's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was $-13.86 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.62 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PureTech Health's annualized ROC % for the quarter that ended in Dec. 2023 was -69.07%. PureTech Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -135.68%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PureTech Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4.75%.

PureTech Health EBIT Historical Data

The historical data trend for PureTech Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health EBIT Chart

PureTech Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

481.12

21.92

-54.24

-88.83

-22.62

PureTech Health Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															37.98	-54.00	-34.84	-8.76	-13.86

Competitive Comparison of PureTech Health's EBIT

For the Biotechnology subindustry, PureTech Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PureTech Health's EV-to-EBIT falls into.

PureTech Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-22.62 Mil.

PureTech Health (OTCPK:PTCHF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PureTech Health's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-140.078 * ( 1 - -83.72% )	/	( (361.723	+	383.502)	/ 2 )
=	-257.3513016	/	372.6125
=	-69.07 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	693.552	-	20.995	-	( 352.139	-	max(0, 49.265	-	360.099	+	352.139	))
=	361.723

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	693.973	-	14.64	-	( 327.143	-	max(0, 51.37	-	347.201	+	327.143	))
=	383.502

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

PureTech Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-27.718	/	( ( (21.497 + max(-35.725, 0))	+	(19.361 + max(-24.219, 0)) )	/	2 )
=	-27.718	/	( ( 21.497	+	19.361 )	/	2 )
=	-27.718	/	20.429
=	-135.68 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.102	+	0	+	5.858)	-	(20.995	+	0	+	22.69)
=	-35.725

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.376	+	0	+	17.682)	-	(14.64	+	0	+	29.637)
=	-24.219

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PureTech Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-22.615	/	475.920
	=	-4.75 %

PureTech Health EBIT Related Terms

Thank you for viewing the detailed overview of PureTech Health's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health (PureTech Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (OTCPK:PTCHF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

PRTC:USA PRTCl:UK PRTC:UK PRTCL:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.